Clinical Trial

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader…

9 months ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation…

9 months ago

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage…

9 months ago

ProofPilot Teams Up with Inspire to Boost Patient Participation in Clinical Trials

NEW YORK, April 1, 2025 /PRNewswire/ -- ProofPilot, the leading end-to-end Clinical Experience Platform (CXP), has partnered with Inspire, the…

9 months ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer,…

9 months ago

Veeva Announces Research Site Clinical Trial Management System

Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsors PLEASANTON, Calif., April 1, 2025 /PRNewswire/ -- Veeva…

9 months ago

NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia

Publication of Independent Study Heightens Demand for UroShield ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company” or “NanoVibronix”), a medical…

9 months ago

CORRECTING and REPLACING ExThera Medical Receives MTEC Award for Pivotal Sepsis Trial

Randomized trial at LSU Health Shreveport will evaluate Seraph 100 Blood Filter's effectiveness in treating sepsis caused by wound infections.…

9 months ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD…

9 months ago